The combination of immunosuppressive drugs and GnRH agonists in this patient’s cancer treatment regimen, along with vascular disruption from the hemangioblastoma itself, may have had a synergistic effect on vasogenic edema development. The gene discussed is GNRH1; the disease is hemangioblastoma.